Latest News Senhwa Biosciences announces first patient dosed in the Phase I/II study of Silmitasertib in children and young adults with relapsed refractory solid tumors Nov 06 2024 Latest News Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director Nov 01 2024 Latest News Senhwa’s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Neuroblastoma Oct 25 2024 Media Coverage Penn State College of Medicine, Beat Childhood Cancer Research Consortium and Four Diamonds launch clinical trial that aims to combat solid tumors Sep 30 2024 Media Coverage Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI Sep 18 2024 Media Coverage AACR 2024 Annual Meeting-Visit Senhwa Biosciences Exhibit Booth Apr 03 2024 Publications Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Sep 24 2022 Publications Protein kinase CK2: a potential therapeutic target for diverse human diseases Jul 20 2021 Publications Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic Dec 17 2020